Corporate venturing unit Amgen Ventures contributed to a $25.5m funding round for the microfluidics healthcare technology developer.

Cowen and European Investment Bank added $52m to a $130m first tranche closed by the AbbVie and Pfizer-backed kidney injury drug developer in July.

The WuXi-backed investment firm returned for a series B2 round that will support phase 1/2 trials for iTeos Therapeutics' oncology therapies.

Autoimmune disease drug developer Pandion Therapeutics closed a series B round co-led by Access Biotechnology and backed by Roche Venture Fund and SR One.

CapitalG returned for a late-stage round that pushed Collibra’s total funding beyond $345m and boosted its valuation to $2.3bn.

The Parkinson's disease therapy developer closed the series A funding less than four months after a Eurofarma-backed seed round.

The enterprise communication platform developer has now raised more than $62m altogether, Dell Technologies Capital leading its latest round.

Intel Capital led a $14.1m round for the cancer diagnostics system provider, its parent company having already supplied it with artificial intelligence technology.

Born out of the Stanford Virtual Human Interaction Lab, Strivr uses virtual reality to train athletes and employees and has now collected $51m in funding altogether.

Based on research at Grousbeck Gene Therapy Center and Massachusetts Eye and Ear, Affinia has raised $60m in a series A round to advance its gene therapies into the clinic.